Erratum to: Selective intraarterial radionuclide therapy with Yttrium-90 (Y-90) microspheres for unresectable primary and metastatic liver tumors

Küçük, Ömer; Soydal, Çiğdem; Lacin, Seda; Özkan, Elgin; Bilgiç, Sadık

doi:10.1186/1477-7819-9-120

Cited by 9 publications

(11 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Though this report focused surgical options for P-NET with liver metastases, novel managements (i.e., PRRT and SIRT) are currently available for unresectable liver metastases, with acceptable side effects [29][30][31][32][33][34] . Effective and beneficial treatment options for P-NET patients with liver metastases should be carefully considered.…”

Section: Discussionmentioning

confidence: 99%

“…Peptide receptor radionuclide therapy (PRRT) with radiolabeled somatostatin analogs is a novel treatment in patients with somatostatin receptor-expressing, welldifferentiated and metastatic neuroendocrine tumors [29][30][31] , and the PRRT with yttrium and/or lutetiumis a potent therapeutic approach. On the other hand, transarterial radioembolisation [i.e., selective internal radiotherapy (SIRT)] is an innovative therapy in liver-limited unresectable, neuroendocrine liver metastases [32][33][34] . SIRT is an effective treatment option for patients with metastatic liver disease in a salvage setting with acceptable toxicity.…”

Section: Management Of Unresectable Liver Metastasesmentioning

confidence: 99%

See 1 more Smart Citation

Pancreatic neuroendocrine tumor accompanied with multiple liver metastases

Hori¹,

Takaori²,

Üemoto³

2014

WJH

View full text Add to dashboard Cite

Pancreatic neuroendocrine tumor (P-NET) is rare and slow-growing. Current classifications predict its prognosis and postoperative recurrence. Curative resection is ideal, although often difficult, because over 80% of patients have unresectable multiple liver metastases and extrahepatic metastasis. Aggressive surgery for liver metastases is important to improve survival. Aggressive or cytoreductive surgery for liver metastases is indicated to reduce hormone levels and improve symptoms and prognosis. Liver transplantation was originally conceived as an ideal therapy for unresectable liver metastases. Unfortunately, there is no clear consensus on the role and timing of surgery for primary tumor and liver metastases. Surgeons still face questions in deciding the best surgical scenario in patients with P-NET with unresectable liver metastases. Key words: Gastroenteropancreatic neuroendocrine tumor; Pancreas; Liver metastasis; Liver surgery; Liver transplantation Core tip: Pancreatic neuroendocrine tumor is rare. Current classifications predict its prognosis and postoperative recurrence. Curative resection is often difficult, because over 80% of patients have unresectable multiple liver metastases and extrahepatic metastasis. Aggressive or cytoreductive surgery for liver metastases is indicated to reduce hormone levels and improve symptoms and prognosis. Liver transplantation was originally conceived as an ideal therapy for unresectable liver metastases. However, there is no clear consensus on the role and timing of surgery for primary tumor and liver metastases.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Management Of Unresectable Liver Metastasesmentioning

confidence: 99%

Pancreatic neuroendocrine tumor accompanied with multiple liver metastases

Hori¹,

Takaori²,

Üemoto³

2014

WJH

View full text Add to dashboard Cite

show abstract

“…Radionuclide therapies are also used for the treatment of a variety of malignancies with 131 I, 90 Y, and 188 Re, polycythemia with 32 P, chronic joint disease with radiosynovectomy, and intravascular radiation therapy (Werner et al, 1957;Domnitz et al, 1960;Osgood, 1968;Silberstein, 1979;Hoefnagel et al, 1987;Chen et al, 1993;Deutsch et al, 1993;Parmentier and Gardet, 1994;Rhodes et al, 1996;Najean and Rain, 1997a;1997b;Tavintharan et al, 1997;Chen et al, 2001;Buchmann et al, 2002;Clunie and Fischer, 2003;Chang et al, 2005;Schneider et al, 2005;Das, 2007;Mortazavi et al, 2007;Turkmen et al, 2007;Ugur et al, 2008;Mumtaz et al, 2009;Schultz et al, 2009;Shamim et al, 2010;de la Corte-Rodriguez et al, 2011;Kucuk et al, 2011;Lacin et al, 2011;Liepe et al, 2011;Liepe, 2012). Table 2 summarises the most commonly used radiopharmaceuticals for targeted radionuclide therapy, including their targeting mechanism and clinical indications.…”

Section: Selected Therapeutic Radionuclides and Their Clinical Applicmentioning

confidence: 99%

Therapeutic radionuclides in nuclear medicine: current and future prospects

Yeong

Cheng

2014

J. Zhejiang Univ. Sci. B

153

115

View full text Add to dashboard Cite

Abstract:The potential use of radionuclides in therapy has been recognized for many decades. A number of radionuclides, such as iodine-131 ( 131 I), phosphorous-32 ( 32 P), strontium-90 ( 90 Sr), and yttrium-90 ( 90 Y), have been used successfully for the treatment of many benign and malignant disorders. Recently, the rapid growth of this branch of nuclear medicine has been stimulated by the introduction of a number of new radionuclides and radiopharmaceuticals for the treatment of metastatic bone pain and neuroendocrine and other malignant or non-malignant tumours. Today, the field of radionuclide therapy is enjoying an exciting phase and is poised for greater growth and development in the coming years. For example, in Asia, the high prevalence of thyroid and liver diseases has prompted many novel developments and clinical trials using targeted radionuclide therapy. This paper reviews the characteristics and clinical applications of the commonly available therapeutic radionuclides, as well as the problems and issues involved in translating novel radionuclides into clinical therapies.

show abstract

“…There have been many literature publications comparing the performance of the two spheres with equal efficacy [16][17][18][19]. The dose for SIRT treatment has been mostly estimated using computed tomography (CT) images [20][21][22][23]. PET has also been recently used for estimating dose and where liver tumor volume and liver tumor contour are combined to estimate dose [24].…”

Section: Y-90 Microparticlesmentioning

confidence: 99%

“…The role of PET in the SIRT treatment has been steadily increasing, not just for treatment planning, but also for prognostic evaluation [25][26][27]. Both tumor volume and standard uptake value are used for prognostic evaluation [22,25,26]. …”

Section: Y-90 Microparticlesmentioning

confidence: 99%

Positron Emission Tomography (PET) Tumor Segmentation and Quantification: Development of New Algorithms

Bhatt¹

View full text Add to dashboard Cite

Professor Anthony McGoron, Major ProfessorTumor functional volume (FV) and its mean activity concentration (mAC) are the quantities derived from positron emission tomography (PET). These quantities are used for estimating radiation dose for a therapy, evaluating the progression of a disease and also use it as a prognostic indicator for predicting outcome. PET images have low resolution, high noise and affected by partial volume effect (PVE). Manually segmenting each tumor is very cumbersome and very hard to reproduce. To solve the above problem I developed an algorithm, called iterative deconvolution thresholding segmentation (IDTS) algorithm; the algorithm segment the tumor, measures the FV, correct for the PVE and calculates mAC. The algorithm corrects for the PVE without the need to estimate camera's point spread function (PSF); also does not require optimizing for a specific camera. My algorithm was tested in physical phantom studies, where hollow spheres (0.5-16 ml) were used to represent tumors with a homogeneous activity distribution. It was also tested on irregular shaped tumors with a heterogeneous activity profile which were acquired using physical and simulated phantom. The physical phantom studies were performed with different signal to background ratios (SBR) and iv with different acquisition times (1-5 min). The algorithm was applied on ten clinical data where the results were compared with manual segmentation and fixed percentage thresholding method called T50 and T60 in which 50% and 60% of the maximum intensity respectively is used as threshold. The average error in FV and mAC calculation was 30% and -35% for 0.5 ml tumor. The average error FV and mAC calculation were ~5% for 16 ml tumor. The overall FV error was ~10% for heterogeneous tumors in physical and simulated phantom data. The FV and mAC error for clinical image compared to manual segmentation was around -17% and 15% respectively. In summary my algorithm has potential to be applied on data acquired from different cameras as its not dependent on knowing the camera's PSF. The algorithm can also improve dose estimation and treatment planning.

show abstract

Erratum to: Selective intraarterial radionuclide therapy with Yttrium-90 (Y-90) microspheres for unresectable primary and metastatic liver tumors

Cited by 9 publications

References 1 publication

Pancreatic neuroendocrine tumor accompanied with multiple liver metastases

Pancreatic neuroendocrine tumor accompanied with multiple liver metastases

Therapeutic radionuclides in nuclear medicine: current and future prospects

Positron Emission Tomography (PET) Tumor Segmentation and Quantification: Development of New Algorithms

Contact Info

Product

Resources

About